These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19898245)

  • 1. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study.
    Papakostas GI; Clain A; Ameral VE; Baer L; Brintz C; Smith WT; Londborg PD; Glaudin V; Painter JR; Fava M
    Int Clin Psychopharmacol; 2010 Jan; 25(1):17-21. PubMed ID: 19898245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms.
    Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D
    Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD; Holman SL; Sayler ME; Potvin JH
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
    Fava M; Schaefer K; Huang H; Wilson A; Iosifescu DV; Mischoulon D; Wessel TC
    J Clin Psychiatry; 2011 Apr; 72(4):473-9. PubMed ID: 21208574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression.
    Londborg PD; Smith WT; Glaudin V; Painter JR
    J Affect Disord; 2000 Dec; 61(1-2):73-9. PubMed ID: 11099743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects.
    Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM
    J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?
    Smith WT; Londborg PD; Glaudin V; Painter JR;
    J Affect Disord; 2002 Aug; 70(3):251-9. PubMed ID: 12128237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
    Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
    Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
    Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
    Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of an acute antidepressant response to fluoxetine and sertraline.
    Flament MF; Lane RM; Zhu R; Ying Z
    Int Clin Psychopharmacol; 1999 Sep; 14(5):259-75. PubMed ID: 10529069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and tolerability of duloxetine in the treatment of anxious versus non-anxious depression: a post-hoc analysis of an open-label outpatient study.
    Fava M; Martinez JM; Greist J; Marangell LB; Brown E; Chen L; Wohlreich MM
    Ann Clin Psychiatry; 2007; 19(3):187-95. PubMed ID: 17729021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study.
    Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S
    Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE; Franznick DA; Hollander SB; Fava M
    J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder.
    Munizza C; Olivieri L; Di Loreto G; Dionisio P
    Curr Med Res Opin; 2006 Sep; 22(9):1703-13. PubMed ID: 16968574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double-blind, randomized trial.
    Amini H; Aghayan S; Jalili SA; Akhondzadeh S; Yahyazadeh O; Pakravan-Nejad M
    J Clin Pharm Ther; 2005 Apr; 30(2):133-8. PubMed ID: 15811165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
    Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
    Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.